Precigen Gains Advantage As PAPZIMEOS Granted Orphan Drug Exclusivity By FDA; Long-Term Data From Clinica
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript